AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35565744
Drug: 4% trehalose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% trehalose solution
Trial: 35565744
Drug: 8% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% glucose solution
Trial: 34520431
Drug: Targeted intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted intravenous albumin infusions
Trial: 32686874
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg TCT daily
Trial: 32686874
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg TCT daily
Trial: 33440964
Drug: Local oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local oxygen therapy (LOT)
Trial: 35276840
Drug: Zinc dispersible
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc dispersible tablet
Trial: 32227161
Drug: Used a
RxNorm normalized name: Sympathomimetics used as decongestants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used a placebo analgesic cream
Trial: 32227161
Drug: Merely possessed
RxNorm normalized name: ZINC OXIDE 17.5 g in 100 g TOPICAL LIPSTICK [Lipshade SPF 30 Obsessed]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Merely possessed a placebo analgesic cream
Trial: 32227161
Drug: Possessed and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Possessed and used a placebo analgesic cream
Trial: 32227161
Drug: Possessed a
RxNorm normalized name: ZINC OXIDE 17.5 g in 100 g TOPICAL LIPSTICK [Lipshade SPF 30 Obsessed]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Possessed a sham cream
Trial: 32890015
Drug: Magnesium infusion
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium infusion (50 mg kg-1 followed by 15 mg kg-1 h-1)
Trial: 33677113
Drug: Immediate spa
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate spa therapy (18 days)
Trial: 33677113
Drug: Delayed spa
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed spa therapy (after 6 months)
Trial: 32331062
Drug: Dasotraline (4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasotraline (4, 6, and 8 mg/d)
Trial: 35137935
Drug: Melatonin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (300 mg capsule)
Trial: 32020523
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day zinc supplement
Trial: 36018353
Drug: Biological xenograft
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological xenograft surgery
Trial: 33100020
Drug: Insulin medications
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin medications
Trial: 33100020
Drug: Non-insulin medications
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-insulin medications
Trial: 33737439
Drug: Medication changes
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication changes
Trial: 34075612
Drug: P218 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P218 (up to 1000 mg)
Trial: 34058250
Drug: Group 1A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1A: 2 sizes larger than the IABF with a 4% taper
Trial: 34058250
Drug: Group 1B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1B: 2 sizes larger than the IABF with a 6% taper
Trial: 34058250
Drug: Group 2A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2A: 3 sizes larger than the IABF with a 4% taper
Trial: 34058250
Drug: Group 2B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2B: 3 sizes larger than the IABF with a 6% taper
Trial: 34941083
Drug: MNF scoring
RxNorm normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNF scoring system (derived from clinical risk factors including female gender, age > 60 years, WBC ≤5000/mm3, WBC ≥35,000/mm3, creatinine ≥1.6 mg/dL, pulse rate >130/min)
Trial: 32705205
Drug: Conventional phacoemulsification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional phacoemulsification treatment (CPCS) + DEX/TOB
Trial: 32451933
Drug: Sulodexide 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulodexide 500 lipasemic units (LSUs) twice daily
Trial: 32451933
Drug: Sulodexide 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulodexide 250 LSU twice daily + indistinguishable placebo
Trial: 35075679
Drug: High-dose dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dual therapy (esomeprazole 20 mg 4 times daily and amoxicillin 1000 mg 3 times daily for 14 days)
Trial: 35075679
Drug: Bismuth-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-containing quadruple therapy (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, and bismuth potassium citrate 220 mg, all twice daily for 14 days)
Trial: 34032663
Drug: Neostigmine (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.07 mg/kg to a maximum of 5 mg)
Trial: 33296786
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane block with 30 ml of 0.2% ropivacaine
Trial: 33296786
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 ml of 0.9% saline)
Trial: 35991210
Drug: LY3127804 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3127804 (20 mg/kg)
Trial: 34463432
Drug: Islatravir (MK-8591)
RxNorm normalized name: vitamin MK 7
DrugBank: Islatravir (DB15653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir (MK-8591) single doses (5 mg to 400 mg)
Trial: 34463432
Drug: Islatravir (MK-8591)
RxNorm normalized name: vitamin MK 7
DrugBank: Islatravir (DB15653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir (MK-8591) multiple doses (10 mg, 30 mg, 100 mg)
Trial: 34463432
Drug: Islatravir (MK-8591)
RxNorm normalized name: vitamin MK 7
DrugBank: Islatravir (DB15653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir (MK-8591) single doses (greater than or equal to 5 mg)
Trial: 32312713
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg SDG/day (Brevail)
Trial: 34693932
Drug: De Simone
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De Simone Formulation Probiotic (DSFP; 'Visbiome') for 48 weeks
Trial: 35829773
Drug: Sodium hypochlorite
RxNorm normalized name: Sodium hypochlorite
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium hypochlorite gel (NaOCl)
Trial: 35829773
Drug: 1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine gel (CHX)
Trial: 33983371
Drug: 3-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day regimen of Pyronaridine-artesunate (180:60 mg)
Trial: 33983371
Drug: 2-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-day regimen of Pyronaridine-artesunate (180:60 mg)
Trial: 33983371
Drug: 1-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-day regimen of Pyronaridine-artesunate (180:60 mg)
Trial: 34229742
Drug: Curcumin-piperine capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin-piperine capsules (3 capsules/day; 1500 mg curcumin and 15 mg piperine daily) for 7 days
Trial: 34229742
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (3 capsules/day; 1515 mg maltodextrin daily) for 7 days
Trial: 34229742
Drug: Curcumin-piperine capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin-piperine capsules
Trial: 36332652
Drug: Combination HIV
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination HIV prevention package including immediate ART initiation
Trial: 36332652
Drug: Combination HIV
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination HIV prevention package excluding immediate ART initiation
Trial: 32343994
Drug: Electronic cigarette
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic cigarette (nicotine concentration of 12 mg/ml)
Trial: 33076964
Drug: Intramuscular 120
RxNorm normalized name: Intramuscular Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 120 mg methylprednisolone followed by methotrexate (increasing dose to 25 mg/week orally)
Trial: 33076964
Drug: Placebo (injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (injection and tablets)
Trial: 33076964
Drug: Intramuscular 120
RxNorm normalized name: Intramuscular Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 120 mg methylprednisolone followed by methotrexate
Trial: 36205701
Drug: Single-point injection
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-point injection of 2 U of botulinum toxin type A per side (simplified method)
Trial: 34481432
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of cytoflavin daily for 10 days
Trial: 34481432
Drug: Standard post-COVID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard post-COVID rehabilitation protocol (pulse magnetic therapy, inhalation therapy, aeroion therapy, infrared laser therapy, course aerobic training, psychotherapy, and standard drug therapy)
Trial: 32726268
Drug: Lactate ≥4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate ≥4 mmol/L
Trial: 32726268
Drug: Lactate ≥7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate ≥7 mmol/L
Trial: 32726268
Drug: Lactate <4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate <4 mmol/L
Trial: 35511718
Drug: Acetazolamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (250 mg 3 times/day)
Trial: 32895056
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with low-molecular-weight heparins/unfractionated heparin subcutaneously
Trial: 32457078
Drug: 250 mcg
RxNorm normalized name: Nplate 250 MCG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mcg methylcobalamin
Trial: 32457078
Drug: 50 mcg
RxNorm normalized name: D3, 50 mcg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mcg (quasi control)
Trial: 35986460
Drug: Remin Pro
RxNorm normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remin Pro Forte (3-month program of hydroxyapatite, fluoride, xylitol, ginger, curcuma-containing cream)
Trial: 35986460
Drug: Remin Pro
RxNorm normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remin Pro (3-month cream regimen including hydroxyapatite and fluoride, xylitol)
Trial: 33608405
Drug: Early closure
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early closure strategy (between 30 and 40 days from rectal surgery)
Trial: 33608405
Drug: Late closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late closure strategy (after the end of adjuvant therapy)
Trial: 33725262
Drug: Prenatal exposure
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal exposure to maternal autoantibodies or anti-rheumatic drugs
Trial: 32281113
Drug: Proximal corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proximal corticosteroid injection (40 mg of methylprednisolone injected 2 cm proximal to the wrist crease)
Trial: 32281113
Drug: Distal corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal corticosteroid injection (40 mg of methylprednisolone injected 2 to 3 cm distal to the wrist crease)
Trial: 32281113
Drug: Proximal corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proximal corticosteroid injection
Trial: 32281113
Drug: Distal corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal corticosteroid injection
Trial: 33565243
Drug: Low-power fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-power fractional CO2 laser combined with topical tranexamic acid (TXA) applied twice a day for 3 weeks, four times in total.
Trial: 33565243
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified what treatment was used).
Trial: 33673786
Drug: Freeze all
RxNorm normalized name: Freez Eez
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze all treatment
Trial: 32171760
Drug: Post-amendment inclusion
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-amendment inclusion criteria requiring elevated natriuretic peptides (B-type natriuretic peptide ≥200 ng/l or N-terminal pro-B-type natriuretic peptide ≥800 ng/l)
Trial: 36094645
Drug: Donanemab (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donanemab (700 mg for the first 3 doses, then 1400 mg every 4 weeks for up to 72 weeks)
Trial: 36070709
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for gestational diabetes
Trial: 35718032
Drug: ZnO–NF1 (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZnO–NF1 (1.5 g/L photocatalyst)
Trial: 35718032
Drug: ZnO–NF2 (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZnO–NF2 (1.5 g/L photocatalyst)
Trial: 35718032
Drug: ZnO–NF2 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZnO–NF2 (2 g/L photocatalyst)
Trial: 32920065
Drug: Riboflavin (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin (1.6 mg/d for 16 weeks)
Trial: 34371324
Drug: Ketadex (dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketadex (dexmedetomidine 0.7 μg/kg and ketamine 1 mg/kg)
Trial: 34371324
Drug: Ketofol (propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketofol (propofol 0.5 mg/kg and ketamine 0.5 mg/kg)
Trial: 34371324
Drug: Ketamine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine alone (1 mg/kg)
Trial: 32825989
Drug: Osteopathic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic treatments (OTs)
Trial: 36117146
Drug: Topical gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical gabapentin 10%
Trial: 35310422
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg mirtazapine tablet
Trial: 35310422
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone diluted in 100 ml of saline infusion
Trial: 33268401
Drug: Flexible gonadotropin-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible gonadotropin-releasing hormone (GnRH) antagonist protocol
Trial: 33268401
Drug: Both PPOS
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both PPOS and GnRH antagonist protocols
Trial: 34717820
Drug: Fluvoxamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (100 mg twice daily for 10 days)
Trial: 34058110
Drug: Medical and
RxNorm normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical and lifestyle therapy
Trial: 35487475
Drug: Ca(OH)2 +
RxNorm normalized name: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca(OH)2 + saline solution (n = 10)
Trial: 35487475
Drug: Ca(OH)2 +
RxNorm normalized name: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca(OH)2 + 2% chlorhexidine-gel (n = 10)
Trial: 35610603
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy‐ Enhanced (CBT‐E)
Trial: 33432016
Drug: Self-administered survey
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered survey on waste management awareness
Trial: 34243076
Drug: Veliparib (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (120 mg orally BID) with carboplatin (AUC 6) and paclitaxel (80 mg/m2)
Trial: 34243076
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with carboplatin (AUC 6) and paclitaxel (80 mg/m2)
Trial: 34243076
Drug: Veliparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (300 mg BID, increasing to 400 mg BID if tolerated)
Trial: 33836814
Drug: Single-injection ultrasound-guided
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection ultrasound-guided thoracic paravertebral block (US-TPVB) with 20 ml of 0.25% ropivacaine
Trial: 33836814
Drug: Oblique subcostal
RxNorm normalized name: Inonotus obliquus fruiting body
DrugBank: Inonotus obliquus fruiting body (DB14332)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oblique subcostal transversus abdominis plane (TAP) block with 20 ml of 0.25% ropivacaine
Trial: 33836814
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic infiltration (LAI) with 40 ml of 0.25% ropivacaine
Trial: 36066078
Drug: Indacaterol (27.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol (27.5 μg) plus glycopyrrolate (15.6 μg) twice daily for 12 weeks
Trial: 32176061
Drug: Apatinib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib combined with carboplatin-paclitaxel or concurrent chemo-brachytherapy (CCBT)
Trial: 32176061
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone or CCBT
Trial: 32176061
Drug: Apatinib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib combined with chemotherapy or CCBT
Trial: 35501515
Drug: Post-infusion cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-infusion cooling time (PICT) of 45 min
Trial: 35501515
Drug: Post-infusion cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-infusion cooling time (PICT) of 20 min
Trial: 35501515
Drug: Standard post-infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard post-infusion cooling time (PICT) of 90 min
Trial: 36348385
Drug: Rucaparib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib 600 mg twice daily as maintenance therapy
Trial: 36348385
Drug: Rucaparib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib 600 mg twice daily as treatment
Trial: 36348385
Drug: Rucaparib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib (both maintenance and treatment)
Trial: 33588088
Drug: CRRT at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRRT at 70 ml/kg/h
Trial: 33588088
Drug: CRRT at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRRT at 35 ml/kg/h
Trial: 35123660
Drug: Baricitinib (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib (4 mg) once daily for up to 14 days plus standard of care
Trial: 32552774
Drug: Oral fluralaner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluralaner (Bravecto®) administered at a minimum dose of 25 mg/kg body weight, one time on Day 0.
Trial: 35853489
Drug: Monthly injection
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly injection (AM)
Trial: 35853489
Drug: Injection every
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection every other month (AEOM)
Trial: 33027403
Drug: Weekly text
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly text messages
Trial: 33027403
Drug: Text message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text message intervention (both weekly and biweekly)
Trial: 35643951
Drug: High-dose prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prednisolone (HDP) 60 mg daily (tapered to 0 mg within 12 weeks)
Trial: 35643951
Drug: Low-dose prednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prednisolone (LDP) 10 mg daily (tapered to 0 mg within 12 weeks)
Trial: 35643951
Drug: High-dose prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prednisolone (HDP)
Trial: 35643951
Drug: Low-dose prednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prednisolone (LDP)